Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019694 · ClinicalTrials.gov registry record · Phase 3
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 470
- Enrollment target
NCT01019694: Completed Phase 3 study, sponsored by Boehringer Ingelheim.
NCT01019694 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 470 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01019694, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 470 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.
Primary Outcome
Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).
Interventions
- DRUG Combivent CFC-MDI
- DRUG Combivent Respimat 20/100 mcg
- DRUG Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2009-11 |
| Phase | Phase 3 |
What the finished NCT01019694 record still lists
NCT01019694 is an interventional study that assigns participants to a tested intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 3 interventions - of which Combivent CFC-MDI is the first listed.
NCT01019694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01019694 about?
NCT01019694 is a clinical study titled "Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease". The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albu...
What is the current status of trial NCT01019694?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 470 participants. The study started on 2009-11.
What interventions are being tested in trial NCT01019694?
The interventions under investigation include: Combivent CFC-MDI (DRUG), Combivent Respimat 20/100 mcg (DRUG), Atrovent HFA 42 mcg + Albuterol HFA 200 mcg (DRUG).
Who is sponsoring clinical trial NCT01019694?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01019694's enrollment target sits among peer trials
470 813th of 2000 higher than 1,186 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia